How did the COVID-19 pandemic affect Stryker's financial performance in Q3 2020?

The COVID-19 pandemic continued to impact Stryker's operations, particularly in the nine-month period, leading to a decline in net sales due to the postponement of deferrable medical procedures. However, the third quarter showed signs of recovery, with a 4.2% increase in net sales driven by improved unit volumes as procedures resumed. The company also focused on cost management, which helped improve operating income and net earnings for the quarter.

What is the financial impact of the pending Wright Medical acquisition?

Stryker announced a definitive agreement to acquire Wright Medical Group for approximately $5.4 billion, expected to close in the fourth quarter of 2020. This acquisition is expected to significantly enhance Stryker's offerings in extremities and biologics within its Orthopaedics segment. While the acquisition cost is substantial, it aligns with Stryker's strategy for growth and market leadership. The company funded its operations and strategic initiatives through debt issuance and its strong cash position.

What is Stryker's current liquidity and financial health?

Stryker maintained a strong liquidity position as of September 30, 2020, with $7.08 billion in cash and cash equivalents. Current assets significantly exceeded current liabilities, indicating good short-term financial health. The company also has access to revolving credit facilities totaling $3.0 billion. Despite the pandemic's challenges, Stryker generated substantial cash from operations, supporting its liquidity needs and strategic investments.

How has Stryker managed its expenses and profitability amidst the pandemic?

Stryker demonstrated effective expense management, particularly in Selling, General, and Administrative (SG&A) expenses, which decreased in Q3 2020 compared to the prior year. This, combined with improved sales volumes in the quarter, led to a significant increase in operating income and a margin expansion to 23.0% for Q3 2020. The company also noted asset impairments related to suspending certain investments due to pandemic-related constraints, primarily impacting the nine-month results.

SYK 10-Q Quarterly Report Q3 FY2020 — Revenue, Net Income, EPS

Summary

Stryker Corporation's third quarter 2020 report (filed October 30, 2020) reflects a company navigating the ongoing impacts of the COVID-19 pandemic. While the nine-month period saw a decline in net sales, the third quarter demonstrated resilience with a 4.2% increase in net sales compared to the prior year, driven by a rebound in unit volumes across key segments. The company managed operating expenses effectively, leading to a significant improvement in operating income and net earnings for the quarter compared to the prior year. Despite the challenges, Stryker continues to invest in its long-term strategy, evidenced by acquisitions and ongoing R&D, though specific asset impairments related to the pandemic's impact were noted. The company also strengthened its financial position by issuing new debt and maintaining a healthy cash position, indicating robust liquidity to manage operations and pursue strategic initiatives, including the significant planned acquisition of Wright Medical Group.

Financial Highlights

51 data points

Beta

Revenue

$3.74B

0.7% Gross Margin

Net Income

$621.00M

0.2% Net Margin

EPS (Diluted)

$1.63

Total Assets

$32.29B

Cash & Equivalents

$7.08B

Free Cash Flow

$760.00M

Financial Statements

Beta

Revenue	$3.74B
Cost of Revenue	$1.28B
Gross Profit	$2.46B
R&D Expenses	$242.00M
SG&A Expenses	$1.24B
Operating Expenses	$1.60B
Operating Income	$859.00M
Net Income	$621.00M
EPS (Basic)	$1.66
EPS (Diluted)	$1.63
Shares Outstanding (Basic)	375.70M
Shares Outstanding (Diluted)	380.20M

Key Highlights

1Q3 2020 Net Sales increased 4.2% year-over-year to $3.74 billion, driven by a recovery in unit volumes across most segments, partially offset by lower prices.
2Nine-month 2020 Net Sales decreased 6.2% to $10.09 billion, significantly impacted by COVID-19 related procedure deferrals.
3Q3 2020 Net Earnings rose 33.3% to $621 million, with Diluted EPS increasing to $1.63 from $1.23 in Q3 2019.
4Operating income for Q3 2020 saw a substantial increase of 36.8% to $859 million, with the operating margin improving to 23.0% from 17.5% in Q3 2019.
5The company has a strong liquidity position with $7.08 billion in cash and cash equivalents as of September 30, 2020.
6Stryker announced a pending acquisition of Wright Medical Group for approximately $5.4 billion, expected to close in Q4 2020, which will bolster its extremities and biologics offerings.
7The company maintained a suspension of its share repurchase program, intending to continue this through 2021, prioritizing capital for strategic investments and operations.

STRYKER CORP Quarterly Report for Q3 Ended Sep 30, 2020

Summary

Financial Highlights

Key Highlights

Frequently Asked Questions